Fig. 1. Summary of the reclassification of the study population according to the 2022 WHO and 2022 ICC classifications. *A case diagnosed as therapy-related myeloid neoplasm according to the 2016 WHO classification is not included in the above figure. It was reclassified as AML, MR post cytotoxic therapy and AML with mutated TP53, therapy-related according to the 2022 WHO and 2022 ICC classifications, respectively.
Abbreviations: MDS-EB, MDS with excess blasts; ICC, International Consensus Classification; IB, increased blasts; MR, myelodysplasia-related; MRC, myelodysplasia-related changes; NOS, not otherwise specified.

Ann Lab Med 2023;43:503~507 https://doi.org/10.3343/alm.2023.43.5.503